May 28-30, 2026
Anargyrios and Korgialenios School, Spetses.
IASIS PHARMA successfully participated in the 9th Panhellenic Conference of S.S.D.V.A.D., titled “SKIN DISEASES 2026: PAST, PRESENT & FUTURE”, held on May 28-30, 2026, at the Anargyrios and Korgialenios School on Spetses island.
The conference was organized by the Society for the Study of Dermatological, Venereological & Allergological Diseases (S.S.D.V.A.D.), chaired by Mr. D. Rigopoulos, Professor Emeritus of Dermatology – Venereology at the NKUA School of Medicine.
At the IASIS PHARMA exhibition booth, the following products were presented:
- Isotroin® / Isotretinoin: This well-established formulation has been enriched with the new and unique 30mg strength, which complements the existing range of dosages (10mg, 20mg & 40mg). Isotroin® is indicated for severe forms of acne resistant to systemic antibiotics and topical therapy.
- Combi®: A combination of fluprednidene (1mg) + miconazole (20mg) in cream form (50gr), indicated for Inflammatory Dermatomycoses.
- Modiwart® / Imiquimod (12.5mg/sachet): An innovative immunomodulator indicated for External Genital Warts, Superficial Basal Cell Carcinomas, and Actinic Keratoses.
- Mastiha var. Chia Cutaneous Regenerative Gel: Since 2015, Chios Mastic has been officially recognized by the European Medicines Agency (EMA) as an Herbal Medicinal Product, with the indication: Skin Inflammations & Healing of Minor Skin Wounds (cutaneous use). It is used for minor skin inflammations and as an aid in healing minor wounds. (Concentration: Each ml of gel contains 10% lyophilized resin of natural Chios mastic Pistacia lentiscus, excipients. 30ml packaging).
